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ABSTRACT
Targeted therapeutic agents, such as inhibitors of epithelial growth factor 
receptor (EGFR), have transformed the management of non-small cell lung cancer 
(NSCLC) patients. MET-amplified NSCLC cells display resistance to EGFR-targeting 
agents, but are addicted to MET signaling for survival and proliferation and are 
sensitive to MET inhibition. However, responsive cancer cells invariably develop 
resistance to MET-targeted treatment.
The tumor microenvironment plays a major role in resistance to anticancer 
therapy. We demonstrated that fibroblasts block the response of MET-amplified NSCLC 
cells to the MET kinase inhibitor, JNJ38877605 in an HGF-dependent manner. Thus, 
MET-amplified NSCLC cells become addicted to HGF upon pharmacological inhibition 
of MET. HGF restored phosphorylation of MET, EGFR and RON, and maintained pro-
survival AKT and ERK signaling in MET-inhibited cells.
We developed a small molecule inhibitor of pro-HGF activation, SRI31215, 
which acts as a triplex inhibitor of the pro-HGF activating proteases matriptase, 
hepsin and HGF activator (HGFA). SRI31215 blocked crosstalk between tumor cells 
and fibroblasts and overcame fibroblast-mediated resistance to MET inhibition by 
preventing fibroblast-mediated reactivation of AKT and ERK signaling. Structurally 
unrelated triplex inhibitors of matriptase, hepsin and HGFA that we developed in 
parallel showed similar biological activity.
Our data suggest that simultaneous inhibition of HGF and MET is required to 
overcome resistance to MET inhibitors in MET-amplified NSCLC cells. This provides 
a rationale for the development of novel combination therapeutic strategies for the 
treatment of NSCLC patients with MET amplification.
INTRODUCTION
Lung cancer remains a leading cause of cancer-
related deaths worldwide. Oncogenic EGFR activation, 
commonly observed in non-small cell lung cancer 
(NSCLC), drives cell proliferation and survival. Indeed, 
EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib 
and erlotinib have become an important therapeutic 
modality for the treatment of NSCLC patients with EGFR 
mutations [1–3]. However, innate or acquired resistance 
limits the efficacy of kinase inhibitors. The presence of 
KRas, BRaf and ERBB2 mutations predicts primary 
resistance to EGFR inhibitors [4, 5]. Acquired resistance 
to EGFR inhibitors has been associated most frequently 
with selection for secondary EGFR mutations, such as 
T790M in exon 20 [6, 7] and with MET amplification [8]. 
Second and third generation EGFR inhibitors have been 
developed and novel combination of these inhibitors with 
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other therapies have been tested to overcome therapeutic 
resistance [9]. Additionally, drugs that target MET are in 
clinical trials to overcome MET-amplification-mediated 
resistance to EGFR inhibitors [10].
MET amplifications have been found in ~20% of 
NSCLC patients with acquired resistance to gefitinib 
or erlotinib [8, 11]. MET-amplified lung cancer cells 
do not respond to EGFR inhibitors [12], but are highly 
sensitive to MET inhibition [13, 14]. Several MET kinase 
inhibitors have been evaluated in clinical trials [15], 
however acquired resistance remains a serious limitation 
of these drugs. Although the mechanisms of resistance 
to MET targeting drugs are not well understood, it has 
been shown that a switch to EGFR dependency can 
underlie the resistance to MET kinase inhibitors. Thus, 
one approach to optimize the anticancer activity and to 
prevent the growth of resistant clones in MET-amplified 
lung cancer cells is the combined therapy with MET 
and EGFR inhibitors [16, 17]. However, lung cancer 
cells with amplified MET and overexpressed EGFR 
frequently show limited response to combined treatment 
[16, 18], underscoring the necessity to identify additional 
mechanism of resistance.
In addition to cell-autonomous mechanisms of 
resistance, factors in the tumor microenvironment have 
been shown to block the response to therapy [19, 20]. 
Stroma-induced resistance to targeted therapy is frequently 
mediated by hepatocyte growth factor (HGF)-induced 
activation of MET [19–21]. HGF activates pro-survival 
signaling and promotes epithelial-mesenchymal transition 
of cancer cells, hindering the response to therapy. HGF 
has been shown to block the response of lung cancer cells 
to EGFR targeting drugs [22, 23] and increased levels of 
serum HGF predict poor progression-free survival and 
overall survival in NSCLC patients treated with EGFR 
inhibitors [24, 25]. Surprisingly, it has recently been 
shown that MET-amplified lung cancer cells become 
dependent on HGF for survival upon pharmacologic MET 
inhibition [26]. This indicates that both HGF and MET 
need to be targeted in MET-amplified NSCLC to prevent 
or to delay the onset of resistance.
Neutralizing anti-HGF antibodies that are being 
tested, alone or in combination with other therapies, 
appear to be well tolerated in clinical trials [27, 28]. 
They have shown encouraging results, yielding partial 
responses in cancer patients. However, there are 
currently no small molecule HGF inhibitors available 
for clinical trials. We developed and characterized two 
distinct series of low molecular weight inhibitors of 
HGF, which act as inhibitors of pro-HGF activation 
[29, 30].
HGF is secreted as a single chain inactive precursor 
called pro-HGF. Proteolytic conversion of pro-HGF to the 
heterodimeric active HGF is required to trigger ligand-
dependent MET signaling. This is achieved by one of the 
trypsin-like serine proteases, matriptase, hepsin or HGF 
activator (HGFA), which are expressed by tumor cells 
[31]. A proteolytically inert mutant form of pro-HGF 
(uncleavable-HGF) or a truncated form of HGF that lacks 
the β-chain (NK4) displayed a competitive antagonism 
with HGF for MET binding. Both mutants suppressed 
proliferation, migration, and invasion of cancer cells and 
inhibited tumor growth and metastasis in vivo [32–35]. 
We demonstrated that triplex inhibitors of matriptase, 
hepsin and HGFA prevent activation of pro-HGF and 
inhibit HGF/MET signaling. SRI31215, a novel inhibitor 
of pro-HGF activation, blocked signaling between tumor-
promoting fibroblasts and colon cancer cells and overcame 
fibroblast-mediated resistance to EGFR inhibitors in colon 
cancer cells [30, 36].
In this study, we established that recombinant HGF or 
HGF-producing fibroblasts protect MET-amplified NSCLC 
cells from MET-targeting therapy by maintaining AKT and 
ERK signaling in MET-inhibited cells. We demonstrated 
that novel inhibitors of HGF activation overcome fibroblast-
mediated resistance to MET inhibition in MET-amplified 
lung cancer cells. This highlights the need to include agents 
blocking the biological activity of HGF, such as inhibitors 
of pro-HGF activation, into therapeutic regimens for MET-
amplified NSCLC patients.
RESULTS
HGF rescues MET-amplified lung cancer cells 
from MET tyrosine kinase inhibition
Whereas MET-amplified lung cancer cells do not 
respond to EGFR inhibition, their growth is strongly 
inhibited by MET tyrosine kinase inhibitors, confirming 
that these cells are addicted to MET signaling [13, 14]. 
Accordingly, the selective MET tyrosine kinase inhibitor, 
JNJ38877605, inhibits the viability of two MET-amplified 
NSCLC cell lines, EBC-1 and H1993 (Figure 1A and 1B). 
Inhibition of HGF using an HGF-specific neutralizing 
antibody had no impact on the viability of EBC-1 or 
H1993 cells (Figure 1A and 1B), confirming that MET 
amplification triggers ligand-independent MET signaling. 
We showed that JNJ38877605 inhibits the viability of 
EBC-1 cells in a dose- and time-dependent manner 
(Supplementary Figure 1A and 1B). In contrast, A549 cells, 
which do not harbor amplified MET, did not respond to the 
growth-inhibitory effect of JNJ38877605 (Figure 1C). This 
demonstrates that MET-amplified lung cancer cells display 
selective sensitivity to MET kinase inhibition.
HGF has been shown to mediate resistance to several 
targeted therapeutic agents such as inhibitors of EGFR, 
BRaf and HER2 [20, 37]. Here we show that HGF also 
blocks the response to JNJ38877605, a specific MET 
kinase inhibitor, in MET-amplified EBC-1 and H1993 
cells (Figure 1D-1F). HGF increased the survival of MET-
inhibited cells in a dose-dependent manner (Supplementary 
Figure 1C). Pro-HGF, the inactive precursor of HGF, was 
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as potent as HGF in protecting EBC-1 and H1993 cells 
from JNJ38877605-induced cell death (Figure 1D-1F), 
confirming that these cell lines express enzyme(s) that can 
activate pro-HGF into its mature form.
These data indicated that MET-amplified NSCLC 
cells rely on HGF for survival upon pharmacological 
inhibition of MET. We have shown earlier that SRI31215, 
a triplex inhibitor of matriptase, hepsin and HGFA, (Figure 
2), inhibits pro-HGF activation [36]. Here we show that 
SRI31215 blocks the pro-survival activity of pro-HGF in 
EBC-1 and H1993 cells (Figure 1D and 1E). Consistent 
with its mode of action, SRI31215 does not impact the 
pro-survival activity of mature HGF (Figure 1D) [36].
The levels of matriptase and hepsin, two of 
the pro-HGF converting enzymes, are significantly 
elevated in lung cancer compared to normal lung tissue 
(Supplementary Figure 2). Moreover, the levels of HGF 
are increased in lung cancer tissue compared to normal 
lung mucosa (Supplementary Figure 2), suggesting that 
inhibition of pro-HGF activation is a valid approach to 
inhibit HGF/MET signaling.
Inhibition of pro-HGF activation overcomes 
fibroblast-mediated resistance to MET kinase 
inhibition
HGF is a key growth factor in the tumor micro-
environment that inhibits the response of cancer cells to 
targeted therapy [20]. Cancer-associated fibroblasts are the 
main source of pro-HGF in the tumor microenvironment, 
therefore we tested whether inhibitors of pro-HGF activation 
can overcome fibroblast–mediated resistance to MET-
targeted therapy. These experiments were performed in the 
absence of serum, which contains enzymes that can cleave 
and activate pro-HGF.
Consistent with our finding that HGF and pro-HGF 
block the activity of JNJ38877605 (Figure 1D and 1E), 
conditioned medium from WI38 lung fibroblasts which 
produce pro-HGF (Supplementary Figure 3A) rescued 
EBC-1 and H1993 cells from JNJ38877605-induced cell 
death (Figure 3A and 3B). We showed that fibroblasts 
with silenced HGF (Supplementary Figure 3A) failed 
to inhibit the response of EBC-1 cells to JNJ38877605 
(Figure 3A). Accordingly, HGF neutralizing antibodies 
blocked the ability of fibroblasts to protect EBC-1 cells 
from JNJ38877605-induced cell death (Figure 3A). 
These experiments established that fibroblasts inhibit 
JNJ38877605-induced cell death through HGF. Consistent 
with published data [17], HGF or fibroblasts did not 
further stimulate MET signaling (Supplementary Figure 
3B) or promote the growth of MET-amplified EBC-1 
(Figure 3A).
Like HGF neutralizing antibodies, SRI31215 
blocked the ability of fibroblasts to rescue EBC-1 and 
H1993 cells from JNJ38877605-induced cell death (Figure 
3A and 3B). Accordingly, the substrate-based peptide 
inhibitors of matriptase, hepsin and HGFA, ZFH7054, 
ZFH7074 and ZFH7116 (Figure 2) restored the sensitivity 
Figure 1: HGF rescues MET-amplified lung cancer cells from MET inhibition. EBC-1 (A) and H1993 (B) MET-amplified 
lung cancer cells, and A549 cells (C) which do not have amplified MET were treated with JNJ38877605 (JNJ) (25 nM) or HGF neutralizing 
antibody (α-HGF Ab). Cell viability was determined after 72 h by CellTiter Glo®. (D and E) EBC-1 and H1993 cells were treated 
with JNJ38877605 (25 nM), HGF (100 nM) or pro-HGF (100 nM) as indicated. Cell viability was determined by CellTiter Glo®. (F) 
Representative images of EBC-1 cells treated with JNJ38877605 alone or with HGF or pro-HGF after 72 h of treatment.
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of EBC-1 cells to JNJ38877605 in the presence of 
fibroblasts and overcame the ability of pro-HGF to rescue 
EBC-1 cells from MET inhibition (Supplementary Figure 
3C). Treatment of EBC-1 cells with SRI31215, ZFH7054, 
ZFH7074 or ZFH7116 alone did not have any impact on 
the viability of EBC-1 cells (Supplementary Figure 3D), 
confirming that these compounds do not target cancer cells 
directly, but inhibit the crosstalk between cancer cells and 
fibroblasts.
To understand the mechanism whereby HGF elicits 
resistance to JNJ38877605, EBC-1 cells were treated with 
JNJ38877605 alone or in the presence of recombinant HGF 
or fibroblasts and SRI31215. As expected, JNJ38877605 
inhibited the expression of p-MET, p-EGFR, p-Gab1, p-ERK 
Figure 2: Molecular structure and activity of SRI31215 (A) and peptide inhibitors of pro-HGF activation, ZFH7054, 
ZFH7074 and ZFH7116 (B). The IC50 values for matriptase, hepsin and HGFA are indicated in bold.
Figure 3: Inhibition of pro-HGF activation overcomes fibroblast-mediated resistance to MET tyrosine kinase inhibition. 
(A) EBC-1 cells were treated with JNJ38877605 (25 nM) alone or in the presence of conditioned medium (CM) from WI38 fibroblasts 
(FIB). CM was also prepared from fibroblasts with silenced HGF (HGF-/- FIB), or from fibroblasts cultured with HGF neutralizing antibody 
(α-HGF Ab) or SRI31215 (10 μM) as indicated. Cell viability was determined by CellTiter Glo®72 h after treatment. (B) H1993 cells were 
treated with JNJ38877605 (25 nM), fibroblast CM (FIB) and SRI31215 (10 μM) as indicated and cell viability was determined after 72 h. 
(C) Serum-starved EBC-1 cells were treated with JNJ38877605, recombinant HGF (100 nM), FIB and SRI31215 (10 μM) as indicated for 
6 hours. Cell lysates were analyzed by immunoblotting for phospho- and total MET, EGFR, Gab1, AKT and ERK 1/2. *, p < 0.05 compared 
to JNJ/FIB.
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1/2 and p-AKT  (Figure 3C). We demonstrated that HGF or 
pro-HGF-producing fibroblasts restored phosphorylation 
of MET, EGFR and Gab1 in JNJ38877605-treated EBC-1 
cells. Accordingly, HGF or fibroblasts reactivated ERK1/2 
and AKT signaling upon pharmacological MET inhibition 
by JNJ38877605. Importantly, SRI31215 blocked fibroblast-
induced MET and EGFR signaling and AKT and ERK 
activation in MET-inhibited cells (Figure 3C), consistent 
with its ability to sensitize EBC-1 and H1993 cells to 
JNJ38877605 (Figure 3A and 3B). The levels of total MET, 
EGFR, Gab1 and AKT were not altered by the treatments 
(Figure 3C). Treatment of cells with HGF, fibroblasts or 
SRI31215 alone did not alter the expression or the activity 
of MET, EGFR, Gab1 or AKT (Supplementary Figure 3B).
Collectively, our data show that fibroblasts elicit 
resistance to MET-targeted therapy through HGF in MET-
amplified lung cancer cells. We showed that HGF is sufficient 
to sustain MET and EGFR signaling and downstream 
activation of ERK and AKT upon MET inhibition. Inhibitors 
of pro-HGF that we developed blocked the pro-survival 
activity of fibroblasts, indicating that dual inhibition of MET 
and HGF is required to overcome resistance to MET-targeted 
therapy in MET-amplified NSCLC.
HGF supports the migration of MET-amplified 
EBC-1 lung cancer cells upon MET tyrosine 
kinase inhibition
MET activation promotes growth, survival and 
stimulates epithelial-mesenchymal transition which 
leads to enhanced migration of cancer cells [38]. 
Indeed, the migration of MET-amplified EBC-1 cells 
was completely inhibited by the MET tyrosine kinase 
inhibitor, JNJ38877605 (Figure 4). The inhibitory effect 
of JNJ38877605 on the migration of EBC-1 cells was 
prevented by either recombinant HGF or by WI38 lung 
fibroblasts (Figure 4). This result established that MET-
amplified NSCLC cells become dependent on HGF not 
only for survival, but also for migration when MET is 
inhibited.
We have shown previously that SRI31215 impedes 
crosstalk between colon cancer cells and fibroblasts and 
thus inhibits the tumor-promoting activities of fibroblasts 
in colon cancer [36]. Here we demonstrate that SRI31215 
blocks the ability of fibroblasts to restore the migration 
of MET-inhibited EBC-1 cells (Figure 4). The peptide 
inhibitors of pro-HGF activation, ZFH7054, ZFH7074 
and ZFH7116 (Figure 2) which target the three pro-HGF 
activating enzymes [29], also blocked fibroblast-mediated 
migration of MET-inhibited EBC-1 cells (Supplementary 
Figure 4). Treatment of cancer cells with inhibitors of pro-
HGF activation alone had no impact on the migration of 
EBC-1 cells (Figure 4 and Supplementary Figure 4).
Thus, while HGF (or fibroblasts) do not further 
stimulate MET signaling (Supplementary Figures 3B 
and 5A) or promote the viability (Figure 3) in MET-
amplified cancer cells, our results established that MET-
amplified NSCLC cells become addicted to HGF upon 
pharmacological MET inhibition. HGF-producing 
fibroblasts promote the survival and migration of 
Figure 4: HGF upholds the migration of MET-addicted EBC-1 lung cancer cells upon MET tyrosine kinase inhibition. 
Migration of EBC-1 cells was assessed by a transwell migration assay. EBC-1 cells were treated with JNJ38877605 (25 nM) in the absence 
or presence of recombinant HGF or conditioned medium from fibroblasts (FIB) and SRI31215 (10 μM) for 24 h. (A) Representative images 
of stained cells that migrated across the polycarbonate membrane. (B) Relative migration of cells was determined by the optical density 
(OD) of stained cells at 560 nm.*, p < 0.05 compared to JNJ/FIB.
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MET-amplified lung cancer cells when MET is inhibited. 
We demonstrated that novel inhibitors of pro-HGF 
processing block crosstalk between tumor cells and 
fibroblasts and thus restrain the tumor-promoting activity 
of fibroblasts.
HGF-induced signaling in MET-inhibited cells
To understand how HGF signals in MET-amplified 
lung cancer cells when MET kinase activity is inhibited, 
we used the Proteome Profiler Human Phospho-RTK array 
(R&D Systems) to investigate the phosphorylation profiles 
of 49 different receptor tyrosine kinases. Additionally, we 
used Phospho-Kinase Array (R&D Systems) containing 46 
kinases and their substrates.
Inhibition of MET kinase by JNJ38877605 
blocked MET phosphorylation, however we showed 
that JNJ38877605 also significantly reduced 
phosphorylation of EGFR, RON (Figure 5A), AXL and 
RET (Supplementary Figure 5A). This suggests that MET 
cross-phosphorylates these RTKs in MET-amplified EBC-
1 cells. Indeed, MET interacts with several other receptor 
tyrosine kinases (RTKs) and MET heterodimers with 
EGFR, RON, HER2 and HER3 have been found abundant 
in MET-amplified cancer cells [39].
HGF restored phosphorylation of MET, EGFR 
and RON in MET-inhibited EBC-1 cells (Figure 
5A, Supplementary Figure 5D), but did not rescue 
phosphorylation of AXL or RET (Supplementary Figure 
5A) in JNJ38877605-treated cells. The array analysis 
confirmed that HGF restored activation of ERK and AKT 
in MET-inhibited cells (Supplementary Figure 5B). In 
addition, we found that WNK1, a prosurvival kinase that 
signals through ERK5 and Wnt [40], is highly activated in 
MET-amplified EBC-1 cells (Supplementary Figure 5C). 
Inhibition of MET kinase by JNJ38877605 significantly 
reduced phosphorylation of WNK1 in EBC-1 cells and 
HGF restored its activity in MET inhibited cells. In contrast, 
the levels of HSP60 were not restored by HGF in MET- 
inhibited cells (Supplementary Figure 5C). This indicates 
that novel mechanisms, such as WNK1 activation, may 
contribute to prosurvival activity of HGF in MET-amplified 
NSCLC cells and maintain the tumor-promoting crosstalk 
between tumor cells and cancer- associated fibroblasts. The 
potential role of WNK1 in HGF signaling and in HGF/
fibroblast-dependent resistance to targeted therapy needs to 
be confirmed in other NSCLC cell lines.
How does HGF signal in MET-inhibited cells? 
It is possible that due to MET overexpression in MET-
amplified cells there is always some residual MET in 
MET- inhibited cells, which responds to HGF stimulation. 
Indeed, we showed that HGF reactivates MET in 
JNJ38877605-treated cells (Figure 3 and Figure 5). 
However, we cannot exclude the possibility that HGF, at 
least in part, promotes survival of MET- amplified cells 
in a MET-independent manner. In fact, HGF stimulation 
increased phosphorylation of MET-related receptor RON, 
HER2, HER3 and RYK, which is likely to contribute to 
the pro-survival activity of HGF (Figure 5B).
DISCUSSION
The tumor-microenvironment plays a major 
role in resistance to targeted therapy. In this study we 
demonstrated that HGF, commonly produced by cancer-
associated fibroblasts, confers resistance to MET kinase 
inhibitors in MET-amplified NSCLC cells. We showed 
that a novel inhibitor of pro-HGF activation, SRI31215, 
blocks the crosstalk between cancer cells and fibroblasts 
and overcomes resistance to anti-MET therapy in MET-
amplified NSCLC cells.
The availability of targeted therapeutic options, 
such as EGFR inhibitors, has improved the management 
of patients with EGFR mutant NSCLC. However, only a 
fraction of patients shows a good clinical response to EGFR 
inhibitors and virtually all patients develop resistance to 
therapy [41–43]. Acquired resistance to EGFR inhibitors 
has been associated most frequently with selection for 
secondary EGFR mutations, such as T790M in exon 20 
[6, 7] and MET amplifications [8]. MET-amplified lung 
cancers, which display ligand-independent MET activation, 
are addicted to MET signaling and are extremely sensitive 
to MET inhibition [13]. Nevertheless, acquired resistance 
to MET kinase inhibitors remains a major limitation of 
these drugs. In some cases, a switch to EGFR dependency 
has been shown to underlie the resistance to MET kinase 
inhibitors [16, 17]. However, some lung cancer cells with 
amplified MET and overexpressed EGFR fail to respond 
to combined treatment with EGFR and MET inhibitors 
or develop resistance to dual EGFR/MET inhibition 
[44]. Indeed, resistance to dual EGFR/MET inhibition 
has recently been reported in a MET-amplified NSCLC 
patient [45].
The tumor microenvironment has been shown to 
elicit resistance to therapy. HGF, which is commonly 
overexpressed in the tumor microenvironment, is a 
frequent source of resistance to targeted therapy [19–21]. 
HGF activates MET, expressed on tumor cells, and drives 
resistance to EGFR-targeted therapy by triggering ERK 
and PI3K/AKT pro-survival signaling and by promoting 
epithelial-mesenchymal transition [20]. Elevated levels 
of circulating HGF are associated with a mesenchymal 
tumor type, poor patient prognosis and resistance to 
EGFR inhibitors in lung cancer patients [11, 25]. Notably, 
EGFR inhibitors have been shown to elevate plasma levels 
of HGF in NSCLC patients [46], which may be due to 
therapy-induced recruitment of fibroblasts. HGF is also 
induced in airway epithelium by smoking [47], by far the 
biggest cause of lung cancer.
Here we demonstrated that HGF also drives 
resistance to anti-MET therapy in MET-amplified lung 
cancer cells (Figure 1 and Figure 3). Thus, MET-amplified 
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NSCLC cells become addicted to HGF upon MET 
inhibition. HGF reactivates MET, EGFR and RON 
phosphorylation and restores AKT, ERK and WNK1 
signaling upon MET inhibition (Figure 3, Figure 5, 
Supplementary Figure 5), promoting the survival of MET-
inhibited cancer cells. Thus, simultaneous inhibition of 
HGF and MET may be required to prevent resistance to 
targeted therapy in MET-amplified NSCLC cells.
Neutralizing anti-HGF antibodies that are being 
tested, alone or in combination with other therapies, appear 
to be well tolerated. They have shown encouraging results, 
yielding partial response in cancer patients [28, 48–51]. 
There are currently no known small molecule inhibitors of 
HGF available, which have several advantages compared 
to therapeutic antibodies [52]. We developed SRI31215, 
a novel small molecule inhibitor of pro-HGF activation, 
which is the rate-limiting step in HGF/MET signaling 
[30]. HGF is synthesized and secreted by tumors or, more 
commonly, by stromal cells as an inactive precursor, pro-
HGF. SRI31215 is a triplex inhibitor of the three serine 
proteases, matriptase, hepsin and HGFA, each of them 
being sufficient for the processing of pro-HGF into the 
biologically active ligand [31]. Structurally distinct 
triplex inhibitors of matriptase, hepsin and HGFA that we 
developed in parallel (Figure 2) exert similar biological 
activity as SRI31215 (Supplementary Figures 3 and 4). 
SRI31215 and the peptide inhibitors mimic the activity 
of Hepatocyte Growth Factor Activator Inhibitors (HAI-
1/2), which act as endogenous inhibitors of pro-HGF 
activation, and inhibit matriptase, hepsin and HGFA [31, 
53]. While HGF-activating enzymes are upregulated in 
lung cancer (Supplementary Figure 2), the levels of HAI-
1/2 are commonly reduced in cancer tissue, resulting in 
increased activation of HGF. Reduced expression of the 
HAIs is associated with advanced stage disease and poor 
prognosis in many cancers [54–60].
We demonstrated previously that SRI31215 
effectively inhibits HGF-dependent MET activation, 
proliferation, epithelial-mesenchymal transition and 
migration of cancer cells and overcomes fibroblast-
mediated resistance to EGFR inhibitors in colon cancer 
cells [36]. Here we established that SRI31215, and 
peptide-based inhibitors of pro-HGF activation, block the 
tumor-promoting activity of fibroblasts and overcome the 
resistance of MET-amplified lung cancer cells to anti-MET 
therapy (Figures 3 and 4). Our preliminary data indicate 
that SRI31215 also overcomes resistance to double MET/
EGFR inhibition (data not shown).
Several MET kinase inhibitors have been developed 
and have entered clinical trials. In preclinical studies 
cancer cells rapidly develop resistance to MET kinase 
inhibitors, which will probably translate to resistance in 
patients. It has been demonstrated that discontinuation of 
MET tyrosine kinase inhibitors results in increased and 
prolonged MET activation, coupled to enhanced tumor 
growth in vitro and in vivo [61], suggesting that MET 
inhibitors will need to be combined with other therapies 
[62].
The mechanisms whereby cancer cells develop 
resistance to MET kinase inhibitors are not well 
understood. Recently, a lung adenocarcinoma patient 
with MET amplification developed resistance to dual 
anti-EGFR/MET therapy due to an acquired METD1228V 
mutation [45]. We demonstrated that HGF, commonly 
overexpressed in the tumor microenvironment, confers 
resistance to MET- targeted therapy in MET-amplified 
Figure 5: HGF-induced signaling in MET inhibited NSCLC cells. EBC-1 cells were treated with JNJ38877605 (25 nM) or HGF 
(100 nM) alone, or with a combination of JNJ38877605 and HGF for 6 hours. Cell lysates were prepared and subjected to antibody-based 
human phospho-receptor tyrosine kinase (RTK) array as described in methods to analyze the phosphorylation profiles of receptor tyrosine 
kinases. *, p < 0.05 compared to JNJ38877605 (JNJ); #, p < 0.05 compared to CTRL.
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NSCLC cells. Thus, small molecule inhibitors of pro-
HGF activation such as those described herein, offer 
a new approach to restore sensitivity to MET or MET/
EGFR inhibition in MET-amplified NSCLC patients. 
Plasma levels of HGF can serve as a biomarker to select 
lung cancer patients that would benefit from drugs that 
counteract the biological activity of HGF.
In summary, our data underscore a key role of the 
tumor microenvironment in acquired resistance to MET 
kinase inhibitors in MET-amplified NSCLC cells. We 
demonstrated that MET-amplified NSCLC cells become 
addicted to HGF under pharmacological MET inhibition. 
Because HGF is frequently overexpressed in the tumor 
microenvironment, our work highlights the need to include 
inhibitors of biological activity of HGF into therapeutic 
regimen in MET-amplified NSCLC patients.
MATERIALS AND METHODS
Materials
Primary antibodies used were anti-MET, anti-
pMET, anti-EGFR, anti-pEGFR, anti-GAB1, anti-pGAB1, 
anti-AKT, anti-pAKT, anti-pERK1/2, (Cell Signaling 
Technology) and anti-β-actin (Sigma). The antibody arrays 
used were Proteome Profiler Human Phospho-Receptor 
Tyrosine Kinase (RTK) (ARY001B) and Phospho-Kinase 
Array (ARY003B) kits from R&D Systems. Recombinant 
HGF and pro-HGF were purchased from R&D Systems. 
The MET kinase inhibitor, JNJ38877605 was purchased 
from Selleck Chemicals (Selleckchem). HGF-specific and 
nonspecific (NSP) siRNAs were purchased from Dharmacon.
Cell culture
A549, WI38 and H1993 cells were obtained from 
ATCC and EBC-1 cells were purchased from XenoTech, 
KS. EBC-1, A549 and WI38 cells were maintained in 
minimum essential medium (MEM) and H1993 cells 
were cultured in RPMI medium. Growth media were 
supplemented with 10% fetal bovine serum, L-glutamine 
and antibiotics and cells were maintained under standard 
cell culture conditions at 37°C and 5% CO2. Conditioned 
medium from fibroblasts was prepared from 18Co 
fibroblasts as reported before [36]. Briefly, fibroblasts 
were maintained in complete medium until they reached 
confluence. The presence of HGF in conditioned media 
was confirmed by immunoblotting and by ELISA as 
described before [36]. Confluent cultures were rinsed and 
maintained in serum-free MEM medium for another 36 
hours. Cell supernatants were collected, centrifuged and 
used immediately or were aliquoted and stored at -80°C.
Transwell migration assay
Cytoselect cell migration assay kit was purchased 
from Cell Biolabs and the assay was performed according 
to the manufacturer’s instructions. EBC-1 cells were 
seeded in transwells (8 μM pore size inserts) at a density 
of 7.5X104 cells/well in serum-free media. Transwells 
were placed in wells (24-well format) containing 10% 
serum-containing media and incubated for 24h. Cells that 
migrated were stained for 10 minutes at room temperature, 
transferred to wells containing 200 μl of extraction buffer 
and incubated for 10 minutes on a shaker. The optical 
density (OD) of stained cells was measured at 560 nm.
Viability assays
CellTiter Glo® luminescent assay kit from Promega 
was used to assess cell viability. Cells were seeded in 96-
well plates at a density of 1X104 cells per well and treated 
as indicated. Cell viability was assessed 24, 48 and 72 hours 
after treatment, following the manufacturer’s protocol.
Immunoblotting
Immunoblotting was performed using standard 
procedures. Proteins were separated by SDS-PAGE. 
Membranes were blocked with 5% non-fat milk in 
Tris-buffered saline with Tween 20 (TBST) for 1 hour 
at room temperature (RT), and immunoblotted with 
primary antibodies in 5% BSA-TBST overnight at 
4°C. Following washing with TBST buffer, membranes 
were incubated with horseradish peroxidase-conjugated 
secondary antibodies for 1 hour and then washed with 
TBST. Membranes were developed using the ECL 
chemiluminescent detection system (Amersham).
Phosphokinase arrays
The phosphorylation profiles of kinases and their 
protein substrates were determined using Proteome 
Profiler Human Phospho-Receptor Tyrosine Kinase 
(RTK) and Human Phospho-Kinase Array kits (R&D 
Systems), following the manufacturers protocol. Serum-
starved EBC-1 cells were treated with JNJ38877605 
for 6h in the absence or presence of recombinant HGF. 
Cells were rinsed with PBS and then solubilized with 
lysis buffer at a concentration of 1X107 cells/mL. Array 
membranes that had been spotted with capture antibodies 
were blocked with blocking buffer and then incubated 
with 300 μg of cell lysates overnight. Arrays were washed 
to remove unbound proteins followed by incubation 
with detection antibodies conjugated to horseradish 
peroxidase. Phosphorylated proteins were detected using 
chemiluminescent reagents and quantified using the Image 
Quant LAS 4000 array analysis software (GE Healthcare 
Life Sciences).
HGF silencing
EBC-1 cells were seeded in a 6-well plate DMEM 
growth medium. Upon reaching 80-90% confluence, 
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growth medium was changed to Opti-MEM and cells were 
transfected with HGF-specific siRNA (Dharmacon) using 
Lipofectamine 2000 (Invitrogen). Non-specific (NSP), 
nontargeting siRNA (Dharmacon) was used as a negative 
control. Both HGF and NSP siRNAs were delivered at a 
final concentration of 25 nM. Growth medium was changed 
to DMEM without antibiotics after overnight transfection. 
HGF silencing was confirmed by immunoblotting.
Statistical analyses
All experiments were repeated at least three times. 
Results are expressed as the mean ± SEM as indicated. 
Statistical analyses using two-tailed student’s t-test were 
performed with the GraphPad Prism 5.0 software. p < 0.05 
was considered statistically significant.
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